var docs;if (!docs) docs =[]; docs["26"]={"2699":"<p><b>Title</b> Abciximab / Dextran</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dextran may enhance the anticoagulant effect of Abciximab. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> IV dextran is contraindicated for use before (or intent to use during) percutaneous coronary intervention (per manufacturer of abciximab).<sup>1</sup></p> \n<p><b>Discussion</b> Eleven patients in the EPIC trial received IV dextran with abciximab. Five of these had major bleeding events and 4 had minor bleeding events compared with 0 of 5 placebo patients who received IV dextran.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Reopro [package insert]. Indianapolis, IN: Eli Lilly and Company, 1998.</p>\n<p>2. EPIC Investigators, “Use of a Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty,” <i>N Engl J Med</i>, 1994, 330(14):956-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8121459\">[PubMed 8121459]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}